Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Oxurion NV Study

This study is currently closed to enrollment.

Oxurion NV / "A Phase 2, randomized, multicenter study to assess the dose level of multiple THR 149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular edema (DME)"

Purpose of the Study

The purpose of this study is to find the best dose of THR-149 and to see how well THR-149 treats diabetic macular edema compared to an approved drug called aflibercept. Aflibercept (Eylea®) has been approved by the FDA to treat diabetic macular edema (DME).